Aimovig vs. Ajovy vs. Emgality: CGRP Antibody Comparison

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 3, 2026 | 8 min read

Aimovig, Ajovy, and Emgality are injectable CGRP monoclonal antibodies for migraine prevention. Aimovig targets the CGRP receptor; Ajovy and Emgality target the CGRP ligand. All three are last-line agents prescribed after oral preventives have failed — and every CGRP prescription carries a documented trail of prior treatment failures that strengthens personal injury claims.

Aimovig vs. Ajovy vs. Emgality: CGRP Antibody Comparison

Aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab) are injectable CGRP (calcitonin gene-related peptide) monoclonal antibodies FDA-approved for the prevention of migraine in adults. They represent the newest and most advanced class of migraine preventive therapy, reserved for patients with severe or refractory migraine who have failed conventional oral preventives. In personal injury cases, a prescription for any of these three drugs documents not only ongoing migraine severity but also a trail of failed prior treatments — because insurance step therapy requirements mandate that patients exhaust cheaper alternatives before CGRP antibodies are authorized.

• Aimovig (erenumab) is the only CGRP antibody that targets the CGRP receptor rather than the CGRP ligand, giving it a distinct mechanism of action
• Ajovy (fremanezumab) offers a quarterly dosing option (675mg every 3 months), reducing injection frequency to just four per year
• Emgality (galcanezumab) holds a unique FDA approval for episodic cluster headache in addition to migraine prevention
• All three require prior authorization from insurance, which means the patient has documented failure of 2-3 oral preventives (topiramate, propranolol, amitriptyline) before reaching this class
• LienScripts generates a POGOS (Pharmacy-Organized General Occurrence Summary) report for every case, providing pharmacist-signed documentation that contextualizes CGRP antibody prescribing within the full medication timeline for demand packages

[!KEY] Every CGRP monoclonal antibody prescription carries an implicit trail of failed prior treatments — insurance step therapy requirements ensure that oral preventives (topiramate, propranolol, amitriptyline) and often acute treatments (triptans) have been tried and found inadequate before authorization is granted.

Understanding the CGRP Pathway and Why It Matters

Calcitonin gene-related peptide (CGRP) is a neuropeptide released by trigeminal nerve fibers during a migraine attack. CGRP causes vasodilation of meningeal blood vessels, triggers neurogenic inflammation, and transmits pain signals through the trigeminal ganglion. Elevated CGRP levels have been measured during migraine attacks, and intravenous CGRP infusion can provoke migraine-like headaches in susceptible individuals.

The three CGRP monoclonal antibodies prevent migraine by interrupting this pathway before it can initiate an attack. However, they do so through two distinct mechanisms:

• Aimovig (erenumab) binds to the CGRP receptor, physically blocking CGRP from activating it
• Ajovy (fremanezumab) and Emgality (galcanezumab) bind to the CGRP ligand itself, neutralizing it before it can reach any receptor

This receptor-vs-ligand distinction is clinically relevant: patients who fail one mechanism may respond to the other. A PI patient who does not respond adequately to Aimovig (receptor blockade) may be switched to Ajovy or Emgality (ligand neutralization), and each switch generates additional specialist documentation of treatment complexity.

Three-Way Comparison Table

Aimovig (Erenumab): The Receptor-Targeting CGRP Antibody

Aimovig was the first CGRP monoclonal antibody to receive FDA approval (May 2018) and remains the only one that targets the CGRP receptor rather than the CGRP ligand. This mechanistic distinction means that erenumab blocks all CGRP signaling at the receptor level, regardless of whether the CGRP came from trigeminal nerve release, parasympathetic pathways, or other sources.

Dosing: Aimovig is available as a 70mg or 140mg monthly subcutaneous injection. The 140mg dose (administered as either one 140mg injection or two 70mg injections) showed superior efficacy in chronic migraine trials and is the dose most commonly used in clinical practice for patients with high migraine frequency.

Clinical evidence: The STRIVE trial demonstrated that erenumab 140mg reduced monthly migraine days by approximately 3.7 days compared to 1.8 for placebo in patients with episodic migraine. In chronic migraine patients (the population most relevant to PI cases), erenumab showed meaningful reductions in headache frequency and acute medication use.

Unique consideration — constipation: Erenumab has a higher incidence of constipation than Ajovy or Emgality, likely because CGRP receptors in the gastrointestinal tract are blocked along with those in the trigeminal system. For PI patients already experiencing constipation from opioid analgesics or reduced mobility, this side effect may influence the choice away from Aimovig.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The receptor-vs-ligand distinction is not academic — it gives neurologists a rational basis for switching between CGRP antibodies when the first one fails, and each switch documents another layer of treatment complexity that strengthens the injury narrative."

[!KEY] Aimovig's unique receptor-targeting mechanism means that a patient who fails Aimovig can be switched to a ligand-targeting antibody (Ajovy or Emgality) with a pharmacologically rational expectation of different results — and each switch generates additional specialist records documenting refractory migraine management.

Ajovy (Fremanezumab): The Quarterly Dosing Option

Ajovy received FDA approval in September 2018 and targets the CGRP ligand rather than its receptor. Its most clinically distinctive feature is the availability of quarterly dosing — 675mg (three 225mg injections administered at the same visit) every three months — in addition to standard monthly dosing at 225mg.

Monthly dosing: 225mg subcutaneous injection once monthly. Comparable efficacy to Aimovig and Emgality for both episodic and chronic migraine prevention.

Quarterly dosing: 675mg subcutaneous injection (three separate 225mg injections at one visit) every three months. The HALO trials demonstrated that quarterly fremanezumab was non-inferior to monthly dosing for migraine prevention — meaning patients receive the same benefit with four dosing events per year rather than twelve.

PI documentation value of quarterly dosing: The quarterly option creates a unique documentation pattern. Each quarterly administration is a single high-value pharmacy dispensing event that covers 90 days of preventive therapy. Over one year of treatment, the patient has four dispensing records — each representing a clinical determination that continued CGRP-level migraine prevention was necessary. Quarterly dosing also demonstrates treatment stability: the patient's migraines are severe enough to require biological prevention but stable enough that the treating neurologist is confident in extending the dosing interval.

Clinical evidence: The HALO-CM trial in chronic migraine patients showed that fremanezumab (both monthly and quarterly) significantly reduced the number of headache days of at least moderate severity compared to placebo. The monthly and quarterly regimens showed similar efficacy profiles.

Emgality (Galcanezumab): The Cluster Headache Distinction

Emgality received FDA approval for migraine prevention in September 2018 and subsequently gained a unique additional indication: prevention of episodic cluster headache. This makes galcanezumab the only CGRP monoclonal antibody — and one of very few medications of any class — with an FDA-approved indication for cluster headache prevention.

Monthly dosing: 120mg subcutaneous injection once monthly, with a 240mg loading dose (two 120mg injections) administered in the first month.

Loading dose significance: The initial 240mg loading dose is clinically meaningful. By administering double the maintenance dose in the first month, the treating physician accelerates the time to therapeutic drug levels, providing faster onset of preventive effect. For PI patients with high migraine frequency who need rapid stabilization, the loading dose strategy documents the urgency of the clinical situation — the neurologist determined that standard monthly buildup was not fast enough.

Cluster headache indication: Cluster headache is one of the most severe pain conditions in medicine, sometimes called "suicide headache" due to its intensity. Post-traumatic cluster headache — triggered or worsened by head injury — is documented in the medical literature. When a neurologist prescribes Emgality for cluster headache prevention in a PI patient, the prescription documents one of the most severe headache disorders recognized in neurology, directly attributed to the head trauma.

Clinical evidence: The EVOLVE-1 and EVOLVE-2 trials demonstrated that galcanezumab 120mg (with 240mg loading dose) reduced monthly migraine days by approximately 4.7 days compared to 2.8 for placebo in episodic migraine. The REGAIN trial confirmed efficacy in chronic migraine. For cluster headache, the Phase 3 trial showed a significant reduction in weekly cluster headache attacks compared to placebo.

[!KEY] Emgality is the only CGRP antibody with FDA approval for episodic cluster headache — one of the most severe pain conditions in medicine. A PI patient prescribed Emgality for post-traumatic cluster headache has documentation of a headache disorder that even defense medical experts cannot characterize as benign.

The Step Therapy Trail: Why CGRP Antibodies Document Treatment Failure

Insurance step therapy protocols require that patients fail two or three oral preventive medications before a CGRP monoclonal antibody is authorized. The specific medications that must be tried and failed typically include:

1. Topiramate — an anticonvulsant with FDA approval for migraine prevention, but with significant side effects (cognitive impairment, weight loss, paresthesias, kidney stones) that PI patients often cannot tolerate
2. Propranolol or other beta-blockers — first-line migraine preventives, but contraindicated in patients with asthma, low blood pressure, or severe fatigue
3. Amitriptyline or nortriptyline — tricyclic antidepressants used off-label for migraine prevention, but with sedation, weight gain, and anticholinergic effects that may compound injury-related symptoms
4. Triptans or other acute treatments — some step therapy protocols also require documented failure of acute migraine medications before authorizing preventive biologics

Every failed medication is documented in the patient's medical records and in the prior authorization submission to the insurer. By the time a CGRP antibody is authorized, the patient has a paper trail of 6-12 months of failed treatments — each one a documented clinical encounter, prescription record, and physician assessment of inadequate response.

For the personal injury case, this step therapy trail is extraordinarily valuable. The prior authorization file itself is a document that summarizes the patient's entire migraine treatment history, the specific medications that failed and why, and the clinical justification for CGRP-level therapy. LienScripts tracks the full medication timeline — including failed therapies — in the POGOS report provided with every case.

When Neurologists Switch Between CGRP Antibodies

Not all patients respond to the first CGRP antibody prescribed. Clinical practice guidelines suggest trialing a CGRP antibody for at least three months before concluding it is ineffective. If the first antibody fails, switching between mechanisms — from receptor blockade (Aimovig) to ligand neutralization (Ajovy or Emgality), or vice versa — is a rational clinical approach supported by emerging evidence.

Each switch generates additional documentation:

• Neurologist assessment of why the first antibody was insufficient
• Prior authorization for the new antibody, which documents the failed trial
• New pharmacy dispensing records under the replacement antibody
• Follow-up evaluations assessing response to the new agent

A PI patient who has trialed two CGRP antibodies has one of the most thoroughly documented migraine conditions in modern neurology. The treating neurologist has exhausted multiple biologic-class agents, each with its own clinical rationale and documented outcome.

What Attorneys Should Know About CGRP Antibody Prescriptions

These Are Last-Line Agents

CGRP monoclonal antibodies are not first-line migraine treatment. They are prescribed after oral preventives have failed, and they require specialty pharmacy routing, prior authorization, and ongoing neurologist management. A PI patient on a CGRP antibody has, by definition, failed multiple cheaper alternatives. This treatment history is itself evidence of migraine severity and treatment complexity.

All Three Are Branded Biologics With No Biosimilars

As of 2026, no biosimilar versions of erenumab, fremanezumab, or galcanezumab have been approved in the United States. All three remain brand-name biologics under patent protection. Defense arguments that the patient should have used a "cheaper generic alternative" fail because no such alternative exists in this drug class.

Monthly or Quarterly Injections Create Consistent Records

Each CGRP antibody injection generates a pharmacy dispensing record. Over a standard 12-month treatment course, this creates 12 monthly records (Aimovig, Emgality, or monthly Ajovy) or 4 quarterly records (quarterly Ajovy). These records objectively document continuous, specialist-directed migraine management that is independent of patient self-report.

CGRP Prescriptions Are Common Adjuster Targets

Because CGRP antibodies are high-value branded biologics, insurance adjusters frequently challenge their inclusion in settlement demands as "excessive." The defense against this challenge is straightforward: the prescriber exhausted every alternative before reaching this class, the patient was clinically evaluated by a neurologist, and no generic or lower-cost alternative exists. The step therapy documentation that preceded the CGRP authorization provides the evidentiary backbone for this defense.

[!KEY] CGRP monoclonal antibodies are common adjuster targets for "excessive charges," but the step therapy prior authorization that preceded every CGRP prescription contains documented proof that the prescriber exhausted all cheaper alternatives — making the "excessive" argument factually unsupportable.

Choosing Between the Three: Clinical Decision Framework

Choose Aimovig when:

• The neurologist wants to start with receptor blockade as a mechanistically distinct first-line biologic approach
• The patient has no significant GI complaints or opioid-induced constipation that could be worsened
• The treating physician is familiar with erenumab as the original CGRP antibody and has the most clinical experience with it

Choose Ajovy when:

• Quarterly dosing is preferred — fewer injections, fewer pharmacy visits, and a simplified administration schedule
• The patient has difficulty with monthly self-injection compliance or has injection-site anxiety
• Treatment stability has been established and the neurologist is confident in extending the dosing interval

Choose Emgality when:

• The patient has been diagnosed with episodic cluster headache — Emgality is the only CGRP antibody with this indication
• The neurologist wants a loading dose strategy for faster onset of preventive effect in patients with high migraine frequency
• The patient has failed a receptor-targeting antibody (Aimovig) and the neurologist wants to trial a ligand-targeting approach

Conclusion

Aimovig, Ajovy, and Emgality are three clinically distinct approaches to CGRP-mediated migraine prevention, each with unique features that determine the treating neurologist's selection. In personal injury cases, the presence of any CGRP monoclonal antibody on a pharmacy lien documents severe, refractory post-traumatic migraine that failed multiple prior treatments — a level of neurological injury documentation that is exceptionally difficult for defense to minimize.

For lien-based coverage of CGRP monoclonal antibodies at $0 upfront cost for qualified personal injury patients, contact LienScripts or visit the attorney portal.

Related Resources

• CGRP Medications: A Complete Guide for Personal Injury
• Aimovig, Emgality, Ajovy, and Vyepti: Injectable CGRP Antibodies for PI
• Sumatriptan vs. Rizatriptan: Triptan Comparison for PI Migraine
• Qulipta vs. Nurtec ODT: Which CGRP Gepant Is Right for PI Patients?
• What Are Medication Liens?